Role of α-Synuclein in Inducing Innate and Adaptive Immunity in Parkinson Disease

Allen Reish, Heather E., Standaert, David G.·2015·Journal of Parkinson’s Disease
DOI 10.3233/jpd-140491

Cited by (243)

Items 101–200 of 243

  1. Phosphorylated α-synuclein aggregated in Schwann cells exacerbates peripheral neuroinflammation and nerve dysfunction in Parkinson’s disease through TLR2/NF-κB pathway
    Sun, Li, Jiang, Wen-Wen, Wang, Ye, Yuan, Yong-Sheng, Rong, Zhe, Wu, Jing, Fan, Yi, Lu, Ming, Zhang, Ke-Zhong · 2021 · Cell Death Discovery
  2. Mediterranean diet protects against a neuroinflammatory cortical transcriptome: Associations with brain volumetrics, peripheral inflammation, social isolation, and anxiety in nonhuman primates (Macaca fascicularis)
    Brett M. Frye, Jacob D. Negrey, Corbin S.C. Johnson, Jeongchul Kim, Richard A. Barcus, Samuel Neal Lockhart, Christopher T. Whitlow, Kenneth L. Chiou, Noah Snyder‐Mackler, Thomas Jude Montine et al. · 2024 · Brain Behavior and Immunity
  3. Inflammation in Experimental Models of α ‐Synucleinopathies
    Ashley S. Harms, Jeffrey H. Kordower, Alessandro Sette, Cecilia S. Lindestam Arlehamn, David L. Sulzer, Robert H. Mach · 2020 · Movement Disorders
  4. Development of immunotherapy and nanoparticles-based strategies for the treatment of Parkinson’s disease
    Ramesh Duwa, Jee‐Heon Jeong, Simmyung Yook · 2021 · Journal of Pharmaceutical Investigation
  5. Dimethyl fumarate ameliorates parkinsonian pathology by modulating autophagy and apoptosis via Nrf2-TIGAR-LAMP2/Cathepsin D axis
    Mayuri Khot, Anika Sood, Kamatham Pushpa Tryphena, Poojitha Pinjala, Saurabh Srivastava, Shashi Bala Singh, Dharmendra Kumar Khatri · 2023 · Brain Research
  6. Tannic Acid Mitigates Rotenone-Induced Dopaminergic Neurodegeneration by Inhibiting Inflammation, Oxidative Stress, Apoptosis, and Glutamate Toxicity in Rats
    Sheikh Azimullah, Mohamed Fizur Nagoor Meeran, Khatija Ayoob, Seenipandi Arunachalam, Shreesh Kumar Ojha, Rami Beiram · 2023 · International Journal of Molecular Sciences
  7. Phosphorylated α-Synuclein Deposits in Cutaneous Nerves of Early Parkinsonism
    Maria Nolano, Giuseppe Caporaso, Fiore Manganelli, Annamaria Stancanelli, Ilaria Borreca, Stefania Mozzillo, Stefano Tozza, Raffaele Dubbioso, Rosa Iodice, Floriana Vitale et al. · 2022 · Journal of Parkinson s Disease
  8. Natural Products as the Potential to Improve Alzheimer’s and Parkinson’s Disease
    Sung Wook Kim, Jun Ho Lee, Bumjung Kim, Gabsik Yang, Jong Uk Kim · 2023 · International Journal of Molecular Sciences
  9. Immunization with α‐synuclein/Grp94 reshapes peripheral immunity and suppresses microgliosis in a chronic Parkinsonism model
    Javier Villadiego, Adahir Labrador‐Garrido, Jaime M. Franco, Magdalena Leal‐Lasarte, Erwin De Genst, Christopher Martin Dobson, David Pozo, Juan José Toledo‐Aral, Cintia Roodveldt · 2017 · Glia
  10. Alpha-synuclein pathology, microgliosis, and parvalbumin neuron loss in the amygdala associated with enhanced fear in the Thy1-aSyn model of Parkinson's disease
    Eileen Ruth S. Torres, Miloš Stanojlović, Moriel Zelikowsky, Jana Bonsberger, Sindalana Hean, Caitlin K. Mulligan, Leonie Baldauf, Sheila M. Fleming, Eliezer Masliah, Marie‐Françoise Chesselet et al. · 2021 · Neurobiology of Disease
  11. Proteomic Profiling of the Substantia Nigra to Identify Determinants of Lewy Body Pathology and Dopaminergic Neuronal Loss
    Vladislav Petyuk, Lei Yu, Heather M. Olson, Fengchao Yu, Gérémy Clair, Weijun Qian, Joshua M Shulman, David Alan Bennett · 2021 · Journal of Proteome Research
  12. RETRACTED ARTICLE: Aging exacerbates the brain inflammatory micro-environment contributing to α-synuclein pathology and functional deficits in a mouse model of DLB/PD
    Michiyo Iba, Ross A. McDevitt, Changyoun Kim, Roshni Roy, Dimitra Sarantopoulou, Ella Tommer, Byron Siegars, Michelle A. Sallin, Somin Kwon, Jyoti Misra Sen et al. · 2022 · Molecular Neurodegeneration · Retracted
  13. Molecular Targets of Valeric Acid: A Bioactive Natural Product for Endocrine, Metabolic, and Immunological Disorders
    Bindu Kumari, Usha Kumari, Dhananjay Kumar Singh, Gulam Mohammed Husain, Dinesh Kumar Patel, Anshul Shakya, Ravi Bhushan Singh, Gyan Prakash Modi, Gireesh Kumar Singh · 2024 · Endocrine Metabolic & Immune Disorders - Drug Targets
  14. Viral-based rodent and nonhuman primate models of multiple system atrophy: Fidelity to the human disease
    David J. Marmion, Angela Rutkowski, Diptaman Chatterjee, Benjamin M. Hiller, Milton H. Werner, Erwan Bézard, Deniz Kirik, Thomas J. McCown, Steven James Gray, Jeffrey H. Kordower · 2020 · Neurobiology of Disease
  15. Mutations in GBA and LRRK2 Are Not Associated with Increased Inflammatory Markers
    Avner Thaler, Nurit Omer, Nir Giladi, Tanya Gurevich, Anat Bar‐Shira, Mali Gana‐Weisz, Orly Goldstein, Meir Kestenbaum, Julia C. Shirvan, Jesse M. Cedarbaum et al. · 2021 · Journal of Parkinson s Disease
  16. Evolving and assembling to pierce through: Evolutionary and structural aspects of antimicrobial peptides
    Sukriyo Chakraborty, Ritika Chatterjee, Dipshikha Chakravortty · 2022 · Computational and Structural Biotechnology Journal
  17. Gene therapy approaches in the non-human primate model of Parkinson’s disease
    Diego Pignataro, Diego Sucunza, Alberto J. Rico, Iria G. Dopeso‐Reyes, Elvira Roda, Ana Isabel Rodriguez-Perez, José Luis Labandeira-García, Vania Broccoli, Shigeki Kato, Kazuto Kobayashi et al. · 2017 · Journal of Neural Transmission
  18. Advantages of Vasoactive Intestinal Peptide for the Future Treatment of Parkinson’s Disease
    Orhan Tansel Korkmaz, Neşe Tunçel · 2019 · Current Pharmaceutical Design
  19. Immunology of West Nile Virus Infection and the Role of Alpha-Synuclein as a Viral Restriction Factor
    Kelsey E. Lesteberg, John David Beckham · 2018 · Viral Immunology
  20. Basic science breaks through: New therapeutic advances in Parkinson's disease
    Patrik Brundin, Graham Atkin, Jennifer T. Lamberts · 2015 · Movement Disorders
  21. Sex and Age Differences in a Progressive Synucleinopathy Mouse Model
    Jérôme Lamontagne‐Proulx, Katherine Coulombe, Marc Morissette, Marie Rieux, Frédéric Calon, Thérèse Di Paolo, Denis Soulet · 2023 · Biomolecules
  22. Protein modification in neurodegenerative diseases
    Shahin Ramazi, Maedeh Dadzadi, Mona Darvazi, Nasrin Seddigh, Abdollah Allahverdi · 2024 · MedComm
  23. Immunoproteasome is up-regulated in rotenone-induced Parkinson’s disease rat model
    Congcong Sun, Guoyong Jia, Xingbang Wang, Yun Wang, Yiming Liu · 2020 · Neuroscience Letters
  24. A Bayesian mathematical model of motor and cognitive outcomes in Parkinson’s disease
    Boris Hayete, Diane Wuest, Jason M. Laramie, Paul D. MCDONAGH, Bruce Church, Shirley W. Eberly, Anthony Edward Lang, KENNETH L. MAREK, Karl Runge, Ira Shoulson et al. · 2017 · PLoS ONE
  25. Effects of lanthanum nitrate on behavioral disorder, neuronal damage and gene expression in different developmental stages of Caenorhabditis elegans
    Gaochao Han, Hai-ming Jing, Wenjing Zhang, Nan Zhang, Zinan Li, Guo‐Yan Zhang, Shan Gao, Junyu Ning, Guojun Li · 2021 · Toxicology
  26. Immunogenetic Determinants of Parkinson’s Disease Etiology
    Pin‐Jui Kung, Inas Elsayed, Paula Reyes‐Pérez, Sara Bandrés‐Ciga · 2022 · Journal of Parkinson s Disease
  27. Targeting α-synuclein as a therapeutic strategy for Parkinson’s disease
    Nada Lawand, Nayef E. Saadé, Omar M. A. El‐Agnaf, Bared Safieh‐Garabedian · 2015 · Expert Opinion on Therapeutic Targets
  28. Nuclear and Mitochondrial Genome, Epigenome and Gut Microbiome: Emerging Molecular Biomarkers for Parkinson’s Disease
    Gleyce Fonseca Cabral, Ana Paula Schaan, Giovanna C. Cavalcante, Camille Sena-dos-Santos, Tatiane Piedade de Souza, Natacha Medeiros de Souza Port’s, Jhully Azevedo dos Santos Pinheiro, Ândrea Ribeiro‐dos‐Santos, Amanda Ferreira Vidal · 2021 · International Journal of Molecular Sciences
  29. Cellular phenotypes as inflammatory mediators in Parkinson’s disease: Interventional targets and role of natural products
    Xu Jiang, Palanivel Ganesan, Thamaraiselvan Rengarajan, Dong‐Kug Choi, Palanisamy Arulselvan · 2018 · Biomedicine & Pharmacotherapy
  30. Exercise for Older Adults Improves the Quality of Life in Parkinson’s Disease and Potentially Enhances the Immune Response to COVID-19
    Mary-Frances E. Hall, Frank Church · 2020 · Brain Sciences
  31. Activation of the immunoproteasome protects SH-SY5Y cells from the toxicity of rotenone
    Congcong Sun, Mingshu Mo, Yun Wang, Wenfei Yu, Chengyuan Song, Xingbang Wang, Si Chen, Yiming Liu · 2019 · NeuroToxicology
  32. NPT520-34 improves neuropathology and motor deficits in a transgenic mouse model of Parkinson’s disease
    Asma Khan, Robert Johnson, Carrie Wittmer, Michelle Maile, Keith J. Tatsukawa, Julian L. Wong, Martin B. Gill, Emily M. Stocking, Srinivasa Reddy Natala, Amy Paulino et al. · 2021 · Brain
  33. Clinical biomarkers for Lewy body diseases
    Mai Mohamed Abdelmoaty, Eugene Lu, Rana Kadry, Emma G. Foster, Shaurav Bhattarai, Rodney Lee Mosley, Howard Eliot Gendelman · 2023 · Cell & Bioscience
  34. Infectious Agents as Potential Drivers of α‐Synucleinopathies
    Morgane Linard, Alix Ravier, Louisa Mougué, Iris Grgurina, Anne‐Laurence Boutillier, Alexandra Foubert‐Samier, Frédéric Blanc, Catherine Helmer · 2022 · Movement Disorders
  35. Chaperome screening leads to identification of Grp94/Gp96 and FKBP4/52 as modulators of the α‐synuclein‐elicited immune response
    Adahir Labrador‐Garrido, Marta Cejudo‐Guillén, Soumya Daturpalli, Magdalena Leal‐Lasarte, Rebecca Klippstein, Erwin De Genst, Javier Villadiego, Juan José Toledo‐Aral, Christopher Martin Dobson, Sophie Jackson et al. · 2015 · The FASEB Journal
  36. Aging and Parkinson’s disease: a complex interplay of vulnerable neurons, the immune system and the blood-brain barrier
    Jonas Bendig, Anika K. Frank, Heinz Reichmann · 2024 · Ageing and Neurodegenerative Diseases
  37. Could α-Synuclein Modulation of Insulin and Dopamine Identify a Novel Link Between Parkinson’s Disease and Diabetes as Well as Potential Therapies?
    Guadalupe Vidal-Martínez, Barbara Carolyn Yang, Javier Vargas‐Medrano, Ruth G. Perez · 2018 · Frontiers in Molecular Neuroscience
  38. α-Synuclein in traumatic and vascular diseases of the central nervous system
    Hong Zeng, Nan Liu, Xiao-Xie Liu, Yanyan Yang, Mouwang Zhou · 2020 · Aging
  39. Fat and Protein Combat Triggers Immunological Weapons of Innate and Adaptive Immune Systems to Launch Neuroinflammation in Parkinson’s Disease
    Shelby Loraine Hatton, Manoj K. Pandey · 2022 · International Journal of Molecular Sciences
  40. A functional role for alpha-synuclein in neuroimmune responses
    Dustin L. Heiden, Brendan Monogue, Muhammad Ali, John David Beckham · 2023 · Journal of Neuroimmunology
  41. Clearing Extracellular Alpha-Synuclein from Cerebrospinal Fluid: A New Therapeutic Strategy in Parkinson’s Disease
    Manuel Menéndez‐González, Huber Padilla-Zambrano, Cristina Tomás‐Zapico, Benjamín Fernández‐Garcia · 2018 · Brain Sciences
  42. Longitudinal in vivo metabolic labeling reveals tissue-specific mitochondrial proteome turnover rates and proteins selectively altered by parkin deficiency
    Kelly L. Stauch, Steven Totusek, Andrew J. Trease, L. Daniel Estrella, Katy M. Emanuel, A. Fangmeier, Howard S. Fox · 2023 · Scientific Reports
  43. Role of Specific Autoantibodies in Neurodegenerative Diseases: Pathogenic Antibodies or Promising Biomarkers for Diagnosis
    Dimitrina Miteva, Georgi Vasilev, Tsvetelina Veselinova Velikova · 2023 · Antibodies
  44. SARS-CoV-2 Spike Protein 1 Causes Aggregation of α-Synuclein via Microglia-Induced Inflammation and Production of Mitochondrial ROS: Potential Therapeutic Applications of Metformin
    Moon Han Chang, Jung Hyun Park, Hye‐Kyung Lee, Ji Young Choi, Young Ho Koh · 2024 · Biomedicines
  45. Conformational Dynamics of α-Synuclein during the Interaction with Phospholipid Nanodiscs by Millisecond Hydrogen–Deuterium Exchange Mass Spectrometry
    Irina Oganesyan, Cristina Lento, Anurag Tandon, Derek J. Wilson · 2021 · Journal of the American Society for Mass Spectrometry
  46. GBA1 and The Immune System: A Potential Role in Parkinson’s Disease?
    Zaid A.M. Al‐Azzawi, Saman Arfaie, Ziv Gan‐Or · 2022 · Journal of Parkinson s Disease
  47. Aging modifies the effect of GCH1 RS11158026 on DAT uptake and Parkinson's disease clinical severity
    Joseph L. Webb, Auriel A. Willette · 2016 · Neurobiology of Aging
  48. TNF-α-NF-κB activation through pathological α-Synuclein disrupts the BBB and exacerbates axonopathy
    Min‐Tae Jeon, Sinnead Anne Cogill, Kyu‐Sung Kim, Yong-Jin Kim, Hye‐Rin Kim, Chung-Yeol Lee, Suji Kim, Suhyeon Son, Jeong-Yeon Kim, Jaehyeok Lee et al. · 2025 · Cell Reports
  49. Pramipexole attenuates 6-OHDA-induced Parkinson’s disease by mediating the Nurr1/NF-κB pathway
    Hua Gao, Dan Wang, Yuling Wang, Jie-ping Mao, Sen Jiang, Xinling Yang · 2021 · Molecular Biology Reports
  50. Nei-like 1 inhibition results in motor dysfunction and promotes inflammation in Parkinson’s disease mice model
    Xue Bai, Wen Qing Xiao, Hong Tian · 2019 · Biochemical and Biophysical Research Communications
  51. [18F]NOS PET Brain Imaging Suggests Elevated Neuroinflammation in Idiopathic Parkinson’s Disease
    Robert K. Doot, Anthony J. Young, Ilya M. Nasrallah, Reagan R. Wetherill, Andrew D. Siderowf, Robert H. Mach, Jacob G. Dubroff · 2022 · Cells
  52. Kinetic control in amyloid polymorphism: Different agitation and solution conditions promote distinct amyloid polymorphs of alpha-synuclein
    Santosh Devi, Dushyant Kumar Garg, Rajiv Bhat · 2023 · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics
  53. Pesticides and the Gut Microbiota: Implications for Parkinson’s Disease
    Ghosh, Nabanita, Sinha, Krishnendu, Sil, Parames C. · 2024 · Chemical Research in Toxicology
  54. Biology, Pathology, and Targeted Therapy of Exosomal Cargoes in Parkinson’s Disease: Advances and Challenges
    Faezeh Almasi, Faeze Abbasloo, Narges Soltani, Masoud Dehbozorgi, Atousa Moghadam Fard, Arash Kiani, Nasim Ghasemzadeh, Hassan Mesgari, Elaheh Zadeh Hosseingholi, Zahra Payandeh et al. · 2025 · Molecular Neurobiology
  55. Air pollution nanoparticle and alpha-synuclein fibrils synergistically decrease glutamate receptor A1, depending upon nPM batch activity
    Hongqiao Zhang, Carla D’Agostino, Christopher T. Tulisiak, Max Andrew Thorwald, Liza Bergkvist, Allison Lindquist, Lindsay K. Meyerdirk, Emily Schulz, Katelyn Becker, Jennifer A. Steiner et al. · 2023 · Heliyon
  56. A Novel Bibenzyl Compound (20C) Protects Mice from 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine/Probenecid Toxicity by Regulating the α-Synuclein–Related Inflammatory Response
    Qiu-Shuang Zhang, Yang Heng, Ying Chen, Piao Luo, Lu Wen, Zhao Zhang, Yu‐He Yuan, Nai‐Hong Chen · 2017 · Journal of Pharmacology and Experimental Therapeutics
  57. Role of rodent models in advancing precision medicine for Parkinson's disease
    Emily Simons, Sheila M. Fleming · 2023 · Handbook of clinical neurology
  58. Exploring the Significance of Microglial Phenotypes and Morphological Diversity in Neuroinflammation and Neurodegenerative Diseases: From Mechanisms to Potential Therapeutic Targets
    Mai M. Anwar, Leonor Pérez‐Martínez, Gustavo Pedraza‐Alva · 2024 · Immunological Investigations
  59. Emerging role of Nrf2 in Parkinson’s disease therapy: a critical reassessment
    Veerta Sharma, Prateek Sharma, Thakur Gurjeet Singh · 2024 · Metabolic Brain Disease
  60. Converging pathologies in neurodegeneration: the mechanistic interplay between α-Synuclein and Tau in Alzheimer’s and Parkinson’s
    Jeyaram Bharathi Jeyabalan, Vignesh Pandi A, Veintramuthu Sankar, Ramasamy Sivasamy, Muralikrishnan Dhanasekaran, Antony Justin · 2025 · Neurological Sciences
  61. Genetic and pharmacological reduction of CDK14 mitigates synucleinopathy
    Jean-Louis A. Parmasad, Konrad M. Ricke, Benjamin Nguyen, Morgan G. Stykel, Brodie Buchner-Duby, Amanda Bruce, Haley M. Geertsma, Eric Y. Lian, Nathalie A. Lengacher, Steve M. Callaghan et al. · 2024 · Cell Death and Disease
  62. Potential role of lactoferrin in early diagnostics and treatment of Parkinson disease
    Sokolov Av, Irina V. Miliukhina, Yury P. Belsky, Nataly V. Belska, V. B. Vasilyev · 2020 · Medical academic journal
  63. Alpha-Synuclein Autoimmune Decline in Prodromal Multiple System Atrophy and Parkinson’s Disease
    Jonas Folke, Emil Bergholt, Bente Pakkenberg, Susana Aznar, Tomasz Brudek · 2022 · International Journal of Molecular Sciences
  64. A comprehensive review on the pharmacological role of gut microbiome in neurodegenerative disorders: potential therapeutic targets
    Namra Aziz, Pranay Wal, Aman Patel, Harshit Prajapati · 2024 · Naunyn-Schmiedeberg s Archives of Pharmacology
  65. Alpha-synuclein shapes monocyte and macrophage cell biology and functions by bridging alterations of autophagy and inflammatory pathways
    Fiona Limanaqi, Silvia Zecchini, Pasquale Ogno, Valentina Artusa, Claudio Fenizia, Irma Saulle, Claudia Vanetti, Micaela Garziano, Sergio Strizzi, Daria Trabattoni et al. · 2024 · Frontiers in Cell and Developmental Biology
  66. The Role of Alpha-Synuclein Autoantibodies in the Induction of Brain Inflammation and Neurodegeneration in Aged Humans
    Manoj K. Pandey · 2022 · Frontiers in Aging Neuroscience
  67. Beneficial effects of cysteamine in Thy1-α-Syn mice and induced pluripotent stem cells with a SNCA gene triplication
    Alberto Siddu, Linda Suzanne David, Nadine D Lauinger, Xiuqing Chen, Martine Saint‐Pierre, Melanie Alpaugh, Thomas M. Durcan, Francesca Cicchetti · 2020 · Neurobiology of Disease
  68. The various facets of protein promiscuity: not just broad specificity of proteins
    Munishwar Nath Gupta, Vladimir Nikolaevich Uversky · 2022 · Elsevier eBooks
  69. Pain in Parkinson's disease: the lived experience
    Doireann Twomey, Samuel Stuart, Katherine Baker · 2018 · International Journal of Therapy and Rehabilitation
  70. Therapeutic Approaches to Non-Motor Symptoms of Parkinson's Disease: A Current Update on Preclinical Evidence
    Poornima D. E. Weerasinghe-Mudiyanselage, Sohi Kang, Joong‐Sun Kim, Changjong Moon · 2022 · Current Neuropharmacology
  71. The Role of Th17 Cells in Immunopathogenesis of Neuroinflammatory Disorders
    Arash Pourgholaminejad, Foozhan Tahmasebinia · 2019 · Contemporary clinical neuroscience
  72. Distinct responses of human peripheral blood cells to different misfolded protein oligomers
    Magdalena Leal‐Lasarte, Benedetta Mannini, Fabrizio Chiti, Michele Vendruscolo, Christopher Martin Dobson, Cintia Roodveldt, David Pozo · 2021 · Immunology
  73. Olfactory Dysfunction: An early indicator of parkinson's disease
    Durlav Chowdhury, Ashmita Das, Mrityunjay Mishra, Jayashree, Arijit Das, Surendra Haribhau Bodakhe · 2025 · Brain Disorders
  74. Modulating the renin-angiotensin system by eprosartan or xanthenone drives microglial M2 polarization in a rat model of Parkinson's disease via regulating the interplay between MKP-1/ miR-155 /SOCS1 and PP2A signaling network
    Maha A. Alhadad, Mai A. Zaafan, Dalia M. El-Tanbouly, Amany I. El-Brairy, Hala Fahmy Zaki · 2025 · International Immunopharmacology
  75. Targeting hypercoagulability in ischemic stroke modulates fibrin-driven microglial polarization via JAK-STAT pathway
    Siyu Guan, Taoyuan Lu, Lei Li, Yong Zhang, Chuan Huang, Chen Li, Bowen Li, Jiayi Hu, Chunxiao Wan · 2025 · Journal of Neuroinflammation
  76. Emerging Targets for the Diagnosis of Parkinson’S Disease: Examination of Systemic Biomarkers
    Lara Cheslow, Adam Eugene Snook, Scott Arthur Waldman · 2021 · Biomarkers in Medicine
  77. MhcII Regulates Transmission of α-Synuclein-Seeded Pathology in Mice
    Elsa Gonzalez De La Cruz, Quan Vo, Katie Moon, Karen N. McFarland, Mary J. Weinrich, Tristan Williams, Benoit I. Giasson, Paramita Chakrabarty · 2022 · International Journal of Molecular Sciences
  78. pNaktide mitigates inflammation-induced neuronal damage and behavioral deficits through the oxidative stress pathway
    Qinglan Zong, Yue Pan, Yongfang Liu, Zhengcun Wu, Zhangqiong Huang, Ying Zhang, Kaili Ma · 2023 · International Immunopharmacology
  79. RAGE Against the Glycation Machine in Synucleinopathies: Time to Explore New Questions
    Daniel Pens Gelain, Reykla Ramon Bittencourt, Luiz Filipe Bastos Mendes, José Cláudio Fonseca Moreira, Tiago F. Outeiro · 2023 · Journal of Parkinson s Disease
  80. Biomolecular changes and cortical neurodegenerative lesions in Trichinella spiralis infected BALB/c mice: a preliminary study elucidating a potential relationship between systemic helminthic infections and idiopathic Parkinson’s
    Marwa A. Hasby Saad, Omnia Safwat El‐Deeb, Dina Magdy El-Guindy, R. Raafat, Dina I. Elgendy, Eiman Adel Hasby · 2018 · Helminthologia
  81. Alpha Synuclein and Parkinson’s Disease
    Arti Parihar, Priyanka Parihar, Isha Solanki, Mordhwaj Singh Parihar · 2018 · Springer eBooks
  82. The quest for Parkinson’s disease biomarkers: traditional and emerging multi-omics approaches
    Pratibha Sharma, Rajinder Kumar Dhamija · 2025 · Molecular Biology Reports
  83. Detecting ferroptosis and immune infiltration profiles in multiple system atrophy using postmortem brain tissue
    Linxi Chen, Lingqun Mao, Hongsheng Lu, Peng Liu · 2023 · Frontiers in Neuroscience
  84. The Spreading and Effects of Human Recombinant α-Synuclein Preformed Fibrils in the Cerebrospinal Fluid of Mice
    Charysse Vandendriessche, Arnout Bruggeman, Joyce Foroozandeh, Lien Van Hoecke, Pieter Dujardin, Junhua Xie, Griet Van Imschoot, Elien Van Wonterghem, Jonas Castelein, Cristiano Lucci et al. · 2024 · eNeuro
  85. Exploring the Link between Periodontal Disease and Systemic Conditions: Implications for Alzheimer’s, Parkinson’s, and Rheumatoid Arthritis
    Kanimozhi, K. Vino Aishwarya, Sweta Yadav, Ajith A. Chandy, Ramyashri Muralikrishna, Rohan Shinkre · 2024 · Journal of Pharmacy And Bioallied Sciences
  86. Disease modifying therapies for Parkinson's disease: Novel targets
    Nirosen Vijiaratnam, Thomas Foltynie · 2021 · Neuropharmacology
  87. Revisiting the alpha-synuclein paradox in melanoma-Parkinson’s disease connection: more than a tale of two cell fates
    Jacopo Aiello, Roberta Zamarato, Claudia Moscheni, Cristiana Perrotta, Mario Clerici, Daria Trabattoni, Mara Biasin, Fiona Limanaqi · 2025 · Cellular and Molecular Life Sciences
  88. Immunotherapy with an antibody against CD1d modulates neuroinflammation in an α-synuclein transgenic model of Lewy body like disease
    Michiyo Iba, Somin Kwon, Changyoun Kim, Marcell P. Szabo, Liam Horan-Portelance, Maria D Lopez-Ocasio, Pradeep Kumar Dagur, Cassia Overk, Robert A. Rissman, Eliezer Masliah · 2024 · Journal of Neuroinflammation
  89. Photobiomodulation in the infrared spectrum reverses the expansion of circulating natural killer cells and brain microglial activation in Sanfilippo mice
    Adeline A. Lau, K. Jin, Helen Beard, T. Windram, Keliang Xie, Jayden A. O'Brien, Daniel Neumann, Barbara M. King, Marten F. Snel, Paul J. Trim et al. · 2024 · Journal of Neurochemistry
  90. TREM2 mediates parkinsonism-like neurodegeneration in carbon disulfide-induced neurotoxicity
    Liu Zhidan, Xianjie Li, Shulin Shan, Qiang Jia, Jianwei Lou, Fuyong Song · 2025 · Neuroscience
  91. Role of Microglial Dysfunction in Parkinson’s Disease: From Multifactorial Causes to Neurodegeneration
    Yuxiang Xu, Tingting Han, Yue Wu, Haixuan Liu, Keyuan Hou, Zhoujie An, Yongjie Li, Chaoyang Zhu, Song Wang, Jianshe Wei · 2025 · Neuroscience Bulletin
  92. Parkinson's disease and comorbid myasthenia gravis: a case report and literature review
    Qihao Zhang, Erhe Xu, Haifeng Li, Piu Chan, Zhenzhen Zhao, Jinghong Ma · 2024 · Frontiers in Neurology
  93. The humoral immune landscape in Parkinson's disease: Unraveling antibody and B cell changes
    Zahra Baridjavadi, Mahmoud Mahmoudi, Narges Abdollahi, Negar Ebadpour, Samaneh Mollazadeh, Dariush Haghmorad, Seyed‐Alireza Esmaeili · 2024 · Cell Biochemistry and Function
  94. Decreased neuronal and increased endothelial fractalkine expression are associated with neuroinflammation in Parkinson’s disease and related disorders
    Yaping Chu, Ashley S. Harms, Ashley V. Boehringer, Jeffrey H. Kordower · 2025 · Frontiers in Cellular Neuroscience
  95. Immunotherapeutic interventions in Parkinson's disease: Focus on α-Synuclein
    Upasana Ganguly, Sukhpal Singh, Sasanka Chakrabarti, Adesh Kumar Saini, Reena Vohra Saini · 2022 · Advances in protein chemistry and structural biology
  96. Adaptive Immunity and Parkinson's Disease
    Wassim Elyaman · 2025 · Cold Spring Harbor Perspectives in Medicine
  97. Reprogramming brain-resident macrophages: from disease drivers to therapeutic allies in neurological disorders
    Peng Zhao, Suyi Li, Qun Liu, Xiao-Chun Peng, L Liu, Fu-Yuan Yang, Chao Wang, Feng Qian, Feng-Ru Tang · 2026 · Frontiers in Cellular Neuroscience
  98. Evidence for prodromal changes in neuronal excitability and neuroinflammation in the hippocampus in young alpha-synuclein (A30P) transgenic mice
    Ibtisam Al-Musawi, Bethany H. Dennis, Gavin John Clowry, Fiona E. N. LeBeau · 2024 · Frontiers in Dementia
  99. A53T mutant α-synuclein fibrils formed in macrophage are spread to neurons
    Shogo Moriya, Michiko Hanazono, Takeshi Fukuhara, Katsuro Iwase, Nobutaka Hattori, Masaki Takiguchi · 2022 · Cellular and Molecular Life Sciences
  100. Causal association between atopic dermatitis and Parkinson's disease: A bidirectional Mendelian randomization study
    Taofeng Zhou, Baohao Wei, Yachun Hu, Xiaoming Zhou, Xiaoying Cai, Xiaolei Shi · 2024 · Brain and Behavior